Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES
AssigneesAbbVie Inc., AbbVie Deutschland GmbH & Co. KG
InventorsStefan Barghorn, Heinz Hillen, Andreas R. Striebinger, Boris Labkovsky, Ulrich Ebert, Patrick Keller
Life of this patent
Estimating the term…
Abstract
The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
Claims34
An isolated antibody having a higher affinity to Aβ(1-42) globulomer than to at least one amyloid beta protein selected from the group consisting of Aβ(1-42) peptide present in cerebrospinal fluid (CSF) and b) Aβ(1-40) peptide present in CSF.
An isolated antibody having a binding affinity to Aβ(1-42) globulomer which is greater than the binding affinity to at least one amyloid beta protein selected from the group consisting of a) Aβ(1-42) monomer, b) Aβ(1-40) monomer, c) Aβ(1-42) fibril and d) soluble amyloid precursor protein-alpha (sAPPα).
8-13. (canceled)
An isolated antibody comprising at least one CDR selected from the group consisting of amino acid sequence:
- a) SHYAWN;
- b) YIDYSGSTRYLPSLKS;
- c) GSGYFYGMDY;
- d) HASQNINVWLS;
- e) KASNLHT;
- f) QQGQSYPYT;
- g) NYLIE;
- h) VINPGSGDTNYNENFKG;
- i) GVITTGFDY;
- j) RASGNIHNYLA;
- k) NAKTLAD and l) QHFWSSPRT.
18-21. (canceled)
30-34. (canceled)
An isolated antibody which binds to at least one epitope of amyloid beta protein in the brain of a patient having amyloidosis.
The kit of claim 46 wherein said antigen is a globulomer.
Dependencies are inferred from the claim text.